<DOC>
	<DOCNO>NCT00695409</DOCNO>
	<brief_summary>This phase II clinical trial study well yttrium Y 90 ibritumomab tiuxetan , rituximab , high-dose chemotherapy follow peripheral blood stem cell transplant treat patient relapse B-cell non-Hodgkin lymphoma . Monoclonal antibody , yttrium Y 90 ibritumomab tiuxetan rituximab , block cancer growth different way . Some block ability cancer cell grow spread . Others find cancer cell help kill carry cancer-killing substance . Radiolabeled monoclonal antibody find tumor cell carry tumor-killing substance without harm normal cell . Giving monoclonal antibody therapy , radioimmunotherapy ( RIT ) , high-dose combination chemotherapy peripheral blood stem cell transplant may effective treatment non-Hodgkin lymphoma .</brief_summary>
	<brief_title>Yttrium Y 90 Ibritumomab Tiuxetan , Rituximab , High-Dose Combination Chemotherapy Followed By Peripheral Blood Stem Cell Transplant Treating Patients With Relapsed B-Cell Non-Hodgkin Lymphoma</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . To estimate progression free/relapse free survival overall survival probability among patient poor risk/relapsed follicular lymphoma ( grade 1-3 ) , mantle cell lymphoma , diffuse large B-cell lymphoma , transform low-grade lymphoma undergo radioimmunotherapy ( RIT ) base autologous stem cell transplant ( ASCT ) . II . To evaluate hematopoietic recovery , use neutrophil ( absolute neutrophil count [ ANC ] &gt; = 500 x 10^3/ul , ANC &gt; = 1000 x 10^3/ul ) unmaintained platelet ( &gt; = 20 x 10^3/ul , &gt; = 100 x 10^3/ul ) engraftment primary criterion , follow RIT base autologous stem cell transplant ( ASCT ) . III . To characterize early late pulmonary , cardiac hepatic toxicity first 100 day post ASCT one year post ASCT . IV . To evaluate response rate disease progression/relapse rate patient treat RIT base ASCT . V. To evaluate long-term incidence myelodysplasia therapy relate acute myeloid leukemia ( AML ) new preparative regimen . VI . To descriptively compare outcomes patient treat protocol comparable patient population treat chemotherapy alone . VII . To perform exploratory study expression costimulatory molecule RIT base ASCT . OUTLINE : RADIOIMMUNOTHERAPY : Patients receive yttrium Y 90 ibritumomab tiuxetan intravenously ( IV ) follow rituximab IV day -14 . HIGH-DOSE COMBINATION CHEMOTHERAPY : Patients receive carmustine IV day -7 -6 ; etoposide IV 1 hour twice daily ( BID ) cytarabine IV 2 hour BID day -5 -2 ; melphalan IV day -1 . STEM CELL TRANSPLANTATION : Patients undergo autologous peripheral blood stem cell transplant day 0 . Patients also receive rituximab day 8* . NOTE : * Some patient may also receive rituximab day -1 . Treatment continue absence disease progression unacceptable toxicity . After completion study treatment , patient follow periodically .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Etoposide phosphate</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<mesh_term>Carmustine</mesh_term>
	<mesh_term>Melphalan</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>All patient must biopsy proven diagnosis low intermediategrade nonHodgkin lymphoma ( NHL ) work formulation B , C , D , E , F , G ; include mantle cell lymphoma ; patient transform lymphoma also eligible Demonstrated monoclonal CD20 positive bcell population lymph node and/or bone marrow Patients must relapse achieve complete partial response prior therapy , never respond prior therapy poor risk disease Patients prior bone marrow involvement must bone marrow aspiration biopsy within 60 day prior stem cell collection show = &lt; 10 % lymphomatous involvement total cellularity ; alternatively , patient prior bone marrow involvement normal bone marrow study show = &lt; 10 % lymphomatous involvement within 28 day salvage chemotherapy Normal renal function test serum creatinine &lt; upper limit normal ( ULN ) , creatinine clearance &gt; = 60 ml/min ( measure calculate ) Adequate pulmonary function measure forced expiratory volume 1 second ( FEV1 ) &gt; 60 % predict measured , diffusion capacity carbon monoxide ( DLCO ) &gt; = 50 % predict measured Cardiac ejection fraction &gt; 50 % echocardiogram multi gate acquisition ( MUGA ) scan ; leave ventricular ejection fraction ( LVEF ) prestudy echocardiogram ( ECHO ) MUGA may use eligibility purpose , even prestudy stress test indicate low LVEF Adequate liver function test bilirubin = &lt; 1.5 x ULN serum glutamic oxaloacetic transaminase ( SGOT ) serum glutamic pyruvic transaminase ( SGPT ) = &lt; 2 x ULN Negative human immunodeficiency virus antibody Eastern Cooperative Oncology Group ( ECOG ) performance status = 0 1 ; karnofsky performance status ( KPS ) &gt; = 80 No active central nervous system ( CNS ) disease prior history CNS disease Patients must recover last therapy least four week prior radiation systemic chemotherapy day administration Y2B8 After last systemic therapeutic chemotherapy ( Cytoxan , administer stem cell mobilization consider therapeutic ) prior initiation high dose treatment , patient baseline compute tomography ( CT ) scan positron emission tomography ( PET ) scan do ; fluorodeoxyglucosecomputed tomography ( FDG/CT ) scan sufficient , however , clinically indicate , additional diagnostic CT may order ; exception : scan do negative disease prior prim chemotherapy ( therapeutic nontherapeutic ) subsequent stem cell harvest , need repeat prior initiation high dose treatment Presence human antiZevalin antibody ( HAZA ) Prior radioimmunotherapy Failure collect adequate number CD34+ cell &gt; = 3 x 10^6/kg Abnormal cytogenetic study relate underlying lymphoma bone marrow aspirate sample prior stem cell collection ; cytogenetics perform marrow aspirate prior stem cell collection , cytogenetics peripheral blood may perform Prior bone marrow transplantation Prior malignancy except : Adequately treat basal cell squamous cell skin cancer Adequately treat noninvasive carcinoma Other cancer patient diseasefree least five year Active evidence Hepatitis B C infection ; Hepatitis B surface antigen positive Patients prior radiation lung exclude study , although mediastinal irradiation permit minimal lung treatment volume Patients receive &gt; 500cGy radiation kidney exclude study Patients pregnant lactate</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>recurrent mantle cell lymphoma</keyword>
	<keyword>stage III mantle cell lymphoma</keyword>
	<keyword>stage IV mantle cell lymphoma</keyword>
	<keyword>recurrent adult diffuse large cell lymphoma</keyword>
	<keyword>stage III adult diffuse large cell lymphoma</keyword>
	<keyword>stage IV adult diffuse large cell lymphoma</keyword>
	<keyword>recurrent grade 1 follicular lymphoma</keyword>
	<keyword>recurrent grade 2 follicular lymphoma</keyword>
	<keyword>recurrent grade 3 follicular lymphoma</keyword>
	<keyword>stage III grade 1 follicular lymphoma</keyword>
	<keyword>stage III grade 2 follicular lymphoma</keyword>
	<keyword>stage III grade 3 follicular lymphoma</keyword>
	<keyword>stage IV grade 1 follicular lymphoma</keyword>
	<keyword>stage IV grade 2 follicular lymphoma</keyword>
	<keyword>stage IV grade 3 follicular lymphoma</keyword>
	<keyword>stage III adult immunoblastic large cell lymphoma</keyword>
	<keyword>stage IV adult immunoblastic large cell lymphoma</keyword>
	<keyword>recurrent adult immunoblastic large cell lymphoma</keyword>
</DOC>